NINDS DTR Community,

The NIH is deeply concerned for the health and safety of people involved in NIH research, and about the effects on the biomedical enterprise by the [HHS declared public health emergency for COVID-19](https://www.hhs.gov/about/coronavirus/index.html). Due to the potential exceptional impact of the public health emergency, we want to assure our recipient community that NIH will be doing our part to help you continue your research. The NIH website on [Coronavirus 2019](https://www.niaid.nih.gov/coronavirus) has a list of available resources. Because of the fluid nature of this situation, we ask that you please check this often for updates.


Over the next 45 days, NIH is urging staff to limit work-related attendance at large meetings, and it is advising that all large NIH-hosted or -organized meetings and symposia either be held virtually using tele/videoconferencing services, postponed, or cancelled. We apologize for any inconvenience to you. You will hear directly from organizers of NIH meetings about these changes. Please visit the NIH website as NIH will be updating this guidance regularly as the situation continues to evolve.

As always, if you have questions or concerns about your grant or application, please reach out to your program officer. We’re here to help.

---

**COVID-19 is an emerging, rapidly evolving situation.**
The Division of Translational Research mission is to accelerate the preclinical discovery and development of new therapeutic interventions for neurological disorders. To facilitate this process, DTR offers a variety of funding opportunities and programs.

- Epilepsy Therapy Screening Program
- Neuroscience Biomarker Program
- IGNITE
- CREATE BIO
- Translational Devices Program
- Small Business Grant Program
- Blueprint Neurotherapeutics Network (BPN)
- CounterACT